Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)
Molecules · 16.02.2024 · 29 (4) · 875
DOI: 10.3390/molecules29040875 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 16.02.2024. Verfasst von Heba T Abdel-Mohsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth S…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert A. Welch Foundation, Prairie View University Faculty.
Abstract (Originalsprache)
Cancer is a complicated, multifaceted disease that can impact any organ in the body. Various chemotherapeutic agents have a low selectivity and are very toxic when used alone or in combination with others. Resistance is one of the most important hurdles that develop due to the use of many anticancer therapeutics. As a result, treating cancer requires a target-specific palliative care strategy. Remarkable scientific discoveries have shed light on several of the molecular mechanisms underlying cancer, resulting in the development of various targeted anticancer agents. One of the most important heterocyclic motifs is quinazoline, which has a wide range of biological uses and chemical reactivities. Newer, more sophisticated medications with quinazoline structures have been found in the last few years, and great strides have been made in creating effective protocols for building these pharmacologically active scaffolds. A new class of chemotherapeutic agents known as quinazoline-based derivatives possessing anticancer properties consists of several well-known compounds that block different protein kinases and other molecular targets. This review highlights recent updates (2021–2024) on various quinazoline-based derivatives acting against different protein kinases as anticancer chemotherapeutics. It also provides guidance for the design and synthesis of novel quinazoline analogues that could serve as lead compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
- Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, Cairo P.O. Box 12622, Egypt.
- Department of Chemistry, Prairie View A & M University, Prairie View, TX 77446, USA.
ORCID-Profile: Heba T Abdel-Mohsen, Sameh H Abdelwahed
Förderung
- Robert A. Welch Foundation
- Prairie View University Faculty
Zitieren
APA
Abdel-Mohsen, H. T., Anwar, M. M., Ahmed, N. S., Abd El-Karim, S. S., & Abdelwahed, S. H. (2024). Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present). Molecules, 29(4), 875. https://doi.org/10.3390/molecules29040875
Vancouver
Abdel-Mohsen HT, Anwar MM, Ahmed NS, Abd El-Karim SS, Abdelwahed SH. Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present). Molecules. 2024;29(4):875. doi:10.3390/molecules29040875
BibTeX
@article{AbdelMohsen2024,
author = {Abdel-Mohsen, Heba T and Anwar, Manal M and Ahmed, Nesreen S and Abd El-Karim, Somaia S and Abdelwahed, Sameh H},
title = {Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)},
journal = {Molecules},
year = {2024},
volume = {29},
number = {4},
pages = {875},
doi = {10.3390/molecules29040875}
}
EUVIMED